



(11)

EP 2 857 041 B9

(12)

## CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

**Corrected version no 1 (W1 B1)****Corrections, see****Description Paragraph(s) 12, 15, 28, 54,  
114, 115**

(51) Int Cl.:

**A61K 49/00 (2006.01)****A61B 17/00 (2006.01)****A61K 9/00 (2006.01)****A61K 47/10 (2017.01)****A61K 47/36 (2006.01)****A61L 24/00 (2006.01)****A61B 18/00 (2006.01)****A61B 17/22 (2006.01)****A61L 24/04 (2006.01)****A61B 17/3205 (2006.01)**

(48) Corrigendum issued on:

**14.02.2018 Bulletin 2018/07**

(45) Date of publication and mention

of the grant of the patent:

**05.04.2017 Bulletin 2017/14**(21) Application number: **14191119.8**(22) Date of filing: **27.04.2006**(54) **Non-lithotriptic kidney-stone therapy**

Nierensteintherapie ohne Lithotripsie

Thérapie de calculs rénaux non lithotriptiques

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR**(30) Priority: **02.05.2005 US 676757 P**

(43) Date of publication of application:

**08.04.2015 Bulletin 2015/15**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

**12193441.8 / 2 601 972****06758729.5 / 1 877 096**

(73) Proprietors:

- Genzyme Corporation  
Cambridge, MA 02142 (US)**
- The General Hospital Corporation  
Boston, MA 02114 (US)**

(72) Inventors:

- McDougal, W., Scott  
Manchester, Massachusetts 01944 (US)**
- Saaco, Dianne, E  
Milton, Massachusetts 02186 (US)**
- Schwarz, Alexander  
Cambridge, Massachusetts 02142 (US)**
- Vogel, Jean-Marie  
Lincoln, Massachusetts 01773 (US)**

(74) Representative: **HGF Limited****1 City Walk  
Leeds LS11 9DX (GB)**

(56) References cited:

**US-A1- 2002 119 116**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****Background of the Invention**

5      **[0001]** Lithiasis is a common human ailment characterized by calculi or "stones" formed within a passage of the human body. While stones have been documented in just about every passage within the body, kidney stones (nephrolithiasis) and gallstones (cholelithiasis) remain the most common. Regardless of its location, however, a stone is typically an extremely hard and unyielding mass which blocks the passage (e.g., lumen) in which it presents.

10     **[0002]** Calculi or stones in the urinary tract or kidneys usually arise because of the breakdown of a delicate balance in the body. Specifically, the kidneys must conserve water to function, but they must excrete materials that have a low solubility. These opposing requirements must be balanced during adaptation to diet, climate and activity. The problem is mitigated to some degree because urine contains substances that inhibit crystallization of stone-forming minerals. However, when urine becomes supersaturated with insoluble materials, because excretion rates are excessive and/or because water conservation is extreme, crystals form and may grow and aggregate to form a stone.

15     **[0003]** Although small crystals are readily voided from the kidney with urine, the larger stones frequently become dislodged from the kidney and enter the ureter or occlude the uretero-pelvic junction, causing obstruction and pain. Although some stones can ultimately traverse the ureter, their passage typically produces pain and bleeding. Usually, the pain is so severe that narcotic drugs are needed for its control.

20     **[0004]** Removal of stones from the kidneys or urinary tract can be effected medically, mechanically or surgically. A well-known surgical approach involves passing a flexible basket in a retrograde manner up the ureter from the bladder, and using the basket to capture the stones. However, the baskets require post-capture removal and only work well for medium-sized stones. Surgery has also been used to remove kidney stones, especially so-called staghorn stones which get lodged in the ureter.

25     **[0005]** Another surgical technique, percutaneous ultrasonic lithotripsy, requires the passage of a rigid cystoscopy-like instrument in the renal pelvis through a small incision in the flank whereupon stones are broken up by a small ultrasound transducer and then removed directly. Another surgical technique is laser lithotripsy via a ureteroscope. All of these procedures, which can be quite painful, are elaborate and expensive, and they do not always result in complete removal of the stones and fragments. One non-invasive technique, known as extracorporeal lithotripsy, entails transmission of high-intensity shock waves from outside the body to fragment the stones within the body. The resulting stone fragments are then voided with urine.

30     **[0006]** Stents have also been used to decompress ureteral obstruction, ensuring that urine drains from the kidney to the bladder. It was recognized that placement of a stent within the ureter could help small stones and stone fragments to transit the ureter. In a typical procedure involving a stent, a guide wire is passed through the ureter to the renal pelvis. A hollow, flexible, cylindrical stent is then advanced with a pusher over the guide wire. The guide wire and pusher are then extracted from the stent and the body, leaving an open lumen for urine to pass through. However, because the lumen defined by the cylindrical stent is even smaller than the ureter itself, all but the smallest stones and sludge are precluded from passing through. In many cases, stone fragments often block the open stent passageway.

35     **[0007]** WO2005037062 discloses injecting temporary plugs in front and behind a concretion (for extracorporeal lithotripsy) or behind a concretion (for intracorporeal lithotripsy). The method of WO2005037062 involves injecting an inverse thermosensitive polymer solution into a lumen, thereby preventing the migration of a concretion, or its fragments, upon extracorporeal or intracorporeal lithotripsy.

**Summary of the Invention**

45     **[0008]** The present invention discloses a medicament comprising a first composition and optionally a second composition, for use in treating lithiasis in a lumen of a mammal, comprising the steps of: injecting into a lumen of a mammal at a first position upstream from a calculi a first composition, wherein said first composition does not contact said calculi and wherein said first composition comprises an inverse thermosensitive polymer; optionally injecting into said lumen at a second position upstream from said calculi a second composition, wherein said second composition does not contact said calculi; wherein (i) said first composition and said second composition admix to form the polymer plug; or (ii) said first composition alone forms a polymer plug; and allowing peristalsis to cause said polymer plug to traverse said lumen, thereby forcing said calculi from said lumen.

**Brief Description of the Figures**

55     **[0009]**

**Figure 1** depicts the deployment of a catheter into a lumen containing a calculi.

**Figure 2** depicts one embodiment of the deployment of a polymer in a lumen at a position upstream from a calculi.  
**Figure 3** depicts the position of the polymer plug and calculi before peristaltic motion.  
**Figure 4** depicts the effect of peristalsis (*i.e.* the movement of the polymer plug towards the outlet of the lumen and the resulting expulsion of the calculi).  
5 **Figure 5** depicts dissolution times under static conditions for purified poloxamer 407 as function of concentration (see Example 3).

### Detailed Description of the Invention


10 **[0010]** One aspect of the present invention provides an approach to the treatment of lithiasis. Importantly, the present invention mitigates the risk of damage to surrounding body tissue when removing a calculi (*e.g.*, biological concretions such as urinary, biliary, and pancreatic stones) which obstructs or may otherwise be present within a body's anatomical lumen. Remarkably, the present invention improves significantly the treatment of lithiasis, while simultaneously reducing the risk of tissue damage and decreasing the procedure time.  
15 **[0011]** In one embodiment, the instant invention provides a method of using a non-tissue adhesive polymer plug to partially or completely occlude a lumen and using the plug to remove calculi and/or calculi fragments from the lumen through the passage of the polymer plug through the lumen due to the natural action of peristalsis on the polymer plug.  
**[0012]** The method is used as an alternative to conventional lithotripsy. The polymer plug is generated *in situ* by temperature change. In some of these embodiments a dual lumen catheter is utilized to inject two solutions proximal to 20 the stone, the mixing of said solutions causing a polymer plug to form. The polymers used in the methods of the invention are inverse thermosensitive polymers. In other embodiment, gel formation due to ionic charges may be used to form a polymer plug. In certain embodiments the polymer plug rapidly dissolves, *e.g.*, in the bladder, after being passed through the lumen.

25 **Definitions**

30 **[0013]** For convenience, certain terms employed in the specification, exemplification, and appended claims are collected here.  
**[0014]** The articles "a" and "an" are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.  
**[0015]** The terms "reversibly gelling" and "inverse thermosensitive" refer to the property of a polymer wherein gelation takes place upon an increase in temperature, rather than a decrease in temperature.  
**[0016]** The term "transition temperature" refers to the temperature or temperature range at which gelation of an inverse thermosensitive polymer occurs.  
35 **[0017]** The term "contrast-enhancing" refers to materials capable of being monitored during injection into a mammalian subject by methods for monitoring and detecting such materials, for example by radiography or fluoroscopy. An example of a contrast-enhancing agent is a radiopaque material. Contrast-enhancing agents including radiopaque materials may be either water soluble or water insoluble. Examples of water soluble radiopaque materials include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble radiopaque materials include 40 metals and metal oxides such as gold, titanium, silver, stainless steel, oxides thereof, aluminum oxide, zirconium oxide, etc.  
**[0018]** As used herein, the term "polymer" means a molecule, formed by the chemical union of two or more oligomer units. The chemical units are normally linked together by covalent linkages. The two or more combining units in a polymer can be the same, in which case the polymer is referred to as a homopolymer. They can be also be different and, thus, the polymer will be a combination of the different units; these polymers are referred to as copolymers.  
45 **[0019]** As used herein, "crosslinking" is when individual polymer chains are linked together by covalent bonds ("chemical crosslinking") or ionic bonds ("ionic crosslinking") to form a three dimensional network. In certain polymers this kind of process has the effect of producing a gel.  
**[0020]** The term "biocompatible", as used herein, refers to having the property of being biologically compatible by not 50 producing a toxic, injurious, or immunological response in living tissue. The term "non-tissue adhesive", as used herein denotes a substance (*e.g.* a polymer plug) does not adhere to biological tissue.  
**[0021]** The term "poloxamer" denotes a symmetrical block copolymer, consisting of a core of PPG polyoxyethylated at both of its terminal hydroxyl groups, *i.e.*, conforming to the interchangeable generic formula  $(PEG)_X-(PPG)_Y-(PEG)_X$  and  $(PEO)_X-(PPO)_Y-(PEO)_X$ . Each poloxamer name ends with an arbitrary code number, which is related to the average 55 numerical values of the respective monomer units denoted by X and Y.  
**[0022]** The term "poloxamine" denotes a polyalkoxylated symmetrical block copolymer of ethylene diamine conforming to the general type  $[(PEG)_X-(PPG)_Y]_2-NCH_2CH_2N-[(PPG)_Y-(PEG)_X]_2$ . Each Poloxamine name is followed by an arbitrary code number, which is related to the average numerical values of the respective monomer units denoted by X and Y.


**[0023]** The term "inverse thermosensitive polymer" as used herein refers to a polymer that is soluble in water at ambient temperature, but at least partially phase-separates out of water at physiological temperature. Inverse thermosensitive polymers include poloxamer 407, poloxamer 188, Pluronic® F127, Pluronic® F68, poly(N-isopropylacrylamide), poly(methyl vinyl ether), poly(N-vinylcaprolactam); and certain poly(organophosphazenes). See Bull. Korean Chem. Soc. 2002, 23, 549-554.

**[0024]** "Alginic acid" as used here in is a naturally occurring hydrophilic colloidal polysaccharide obtained from the various species of brown seaweed (*Phaeophyceae*). It occurs in white to yellowish brown filamentous, grainy, granular or powdered forms. It is a linear copolymer consisting mainly of residues of  $\beta$ -1,4-linked D-mannuronic acid and  $\alpha$ -1,4-linked L-glucuronic acid. These monomers are often arranged in homopolymeric blocks separated by regions approximating an alternating sequence of the two acid monomers, as shown below:




The formula weight of the structural unit is 176.13 (theoretical; 200 is the actual average). The formula weight of the macromolecule ranges from about 10,000 to about 600,000 (typical average).

**[0025]** "Sodium alginate" and "potassium alginate" are salts of alginic acid. For example, "potassium alginate" is shown below:



**[0026]** "Gellan gum" is a high molecular weight polysaccharide gum produced by a pure culture fermentation of a carbohydrate by *Pseudomonas elodea*, purified by recovery with isopropyl alcohol, dried, and milled. The high molecular weight polysaccharide is principally composed of a tetrasaccharide repeating unit of one rhamnose, one glucuronic acid, and two glucose units, and is substituted with acyl (glyceryl and acetyl) groups as the O-glycosidically-linked esters. The glucuronic acid is neutralized to a mixed potassium, sodium, calcium, and magnesium salt. It usually contains a small amount of nitrogen containing compounds resulting from the fermentation procedures. It has a formula weight of about 500,000. "Sodium gellan" and "potassium gellan" are salts of gellan gum.

**[0027]** Carboxymethylcellulose (CMC) is a polymer derived from natural cellulose. Unlike cellulose, CMC is highly water-soluble. The CMC structure is based on the  $\beta$ -(1 $\rightarrow$ 4)-D-glucopyranose polymer of cellulose. Different preparations may have different degrees of substitution, but it is generally in the range 0.6 - 0.95 derivatives per monomer unit, as shown below:




[0028] CMC molecules are somewhat shorter, on average, than native cellulose with uneven derivatization giving areas of high and low substitution. This substitution is mostly 2-O- and 6-O-linked, followed in order of importance by 2,6-di-O- then 3-O-, 3,6-di-O-, 2,3-di-O- lastly 2,3,6-tri-O-linked. It appears that the substitution process is a slightly cooperative (within residues) rather than random process giving slightly higher than expected unsubstituted and trisubstituted areas. CMC molecules are most extended (rod-like) at low concentrations but at higher concentrations the molecules overlap and coil up and then, at high concentrations, entangle to become a thermoreversible gel. Increasing ionic strength and reducing pH both decrease the viscosity as they cause the polymer to become more coiled. The average chain length and degree of substitution are of great importance; the more-hydrophobic lower substituted CMCs are thixotropic but more-extended higher substituted CMCs are pseudoplastic. At low pH, CMC may form crosslinks through lactonization between carboxylic acid and free hydroxyl groups.

15

20

25

[0029] "Poly vinyl alcohol" (PVA) is a water soluble polymer synthesized by hydrolysis of a poly vinyl ester such as the acetate and used for preparation of fibers. PVA a thermoplastic that is produced from full or partial hydrolysis of vinyl ester such as vinyl acetate resulting in the replacement of some or all of the acetyl groups with hydroxyl groups. For example:




In certain embodiments polyvinyl alcohol (PVA) is a synthetic resin produced by polymerisation of vinyl acetate (VAM) followed by hydrolysis of the polyvinyl acetate (PVAc) polymer. The degree of polymerisation determines the molecular weight and viscosity in solution. The degree of hydrolysis (saponification) signifies the extent of conversion of the Polyvinyl Acetate to the Polyvinyl Alcohol For example n (Degree of Hydrolysis) may be in the range of about 68.2 to about 99.8 mol.% and the MW (Weight Average Molecular Weight) may range from about 10.000 to about 190,000.

35

40

[0030] Hyaluronic acid (HA) is a polymer composed of repeating dimeric units of glucuronic acid and N-acetyl glucosamine. It may be of extremely high molecular weight (up to several million daltons) and forms the core of complex proteoglycan aggregates found in extracellular matrix. HA is comprised of linear, unbranching, polyanionic disaccharide units consisting of glucuronic acid (GlcUA) an N-acetyl glucosamine (GlcNAc) joined alternately by  $\beta$ -1-3 and  $\beta$ -1-4 glycosidic bonds (see below). It is a member of the glycosaminoglycan family which includes chondroitin sulphate, dermatan sulphate and heparan sulphate. Unlike other members of this family, it is not found covalently bound to proteins.



55

[0031] When incorporated into a neutral aqueous solution hydrogen bond formation occurs between water molecules and adjacent carboxyl and N-acetyl groups. This imparts a conformational stiffness to the polymer, which limits its flexibility. The hydrogen bond formation results in the unique water-binding and retention capacity of the polymer. It also

follows that the water-binding capacity is directly related to the molecular weight of the molecule. Up to six liters of water may be bound per gram of HA.

**[0032]** HA solutions are characteristically viscoelastic and pseudoplastic. This rheology is found even in very dilute solutions of the polymer where very viscous gels are formed. The viscoelastic property of HA solutions which is important in its use as a biomaterial is controlled by the concentration and molecular weight of the HA chains. The molecular weight of HA from different sources is polydisperse and highly variable ranging from  $10^4$  to  $10^7$  Da. The extrusion of HA through the cell membrane as it is produced permits unconstrained polymer elongation and hence a very high molecular weight molecule.

**[0033]** The phrase "polydispersity index" refers to the ratio of the "weight average molecular weight" to the "number average molecular weight" for a particular polymer; it reflects the distribution of individual molecular weights in a polymer sample.

**[0034]** The phrase "weight average molecular weight" refers to a particular measure of the molecular weight of a polymer. The weight average molecular weight is calculated as follows: determine the molecular weight of a number of polymer molecules; add the squares of these weights; and then divide by the total weight of the molecules.

**[0035]** The phrase "number average molecular weight" refers to a particular measure of the molecular weight of a polymer. The number average molecular weight is the common average of the molecular weights of the individual polymer molecules. It is determined by measuring the molecular weight of  $n$  polymer molecules, summing the weights, and dividing by  $n$ .

**[0036]** The terms "calculi" and "calculus" denote one or more masses or nodules of solid matter formed by growing together, by congelation, condensation, coagulation, induration, etc. Common synonyms, for example, are concretions, stones, clots, tones or lumps. Often, in an organism a concretion is a hard lump of mineral salts found in a hollow organ or duct. In one embodiment, concretion refers to stone-like objects found within an organ (e.g., the kidneys) of an organism.

**[0037]** The term "lumen" denotes the space enclosed by a tube-like structure or hollow organ, such as inside an artery, a vein, a kidney, a gall bladder, a ureter, a urinary bladder, a pancreas, a salivary gland, a small intestine or a large intestine (i.e., an opening, space, or cavity in a biological system). A lumen has an "inlet" and an "outlet" based on the direction of the flow of materials through the lumen. As used here "upstream" from a given object in a lumen means between said object and the inlet of the lumen; "downstream" from a given object in a lumen means between said object and the outlet of the lumen.

**[0038]** "Peristalsis" as used herein refers to a series of coordinated, rhythmic muscle contractions. For example, it is an automatic and vital process that moves food through the digestive tract, urine from the kidneys through the ureters into the bladder, and bile from the gallbladder into the duodenum. Peristalsis moves material in a lumen towards the outlet of the lumen.

**[0039]** "Lithotripsy" as used herein refers to any procedure, surgery or technique that fragments or breaks up a stone.

**[0040]** "Lithiasis" as used herein refers to a common human ailment characterized by calculi or "stones" formed within a passage or lumen of a human.

### Calculi

**[0041]** Calculi can develop in parts of the body, such as in the kidneys, pancreas, ureter and gallbladder. It is not uncommon for biological calculi to be referred to as stones, especially when they are composed of mineral salts. For example, calculi formed in the biliary system are called gallstones. Those that form in the bladder are often known as vesical calculi or bladder stones. Calculi occurring in the kidney are often called kidney stones. Calculi can also occur in the ureter; there they are usually the result of the incomplete passage of a calculi originating in a kidney. It is also possible to observe a calculi in a salivary duct or gland.

**[0042]** There are four main types of calculi observed biologically. The majority of calculi, about 75%, are calcium-containing, composed of calcium oxalate, sometimes mixed with calcium phosphate. Another 15% are composed of magnesium ammonium phosphate; these calculi are often referred to as "triple stones" or struvite stones. The bulk of the remaining stones are made up of uric acid or cystine (Cys-Cys). As mentioned above, when calculi are too large to pass spontaneously, medical intervention is often needed.

### Polymers of the Invention

**[0043]** A polymer plug is generated in situ by one or more physical phenomena, such as temperature, pH changes and/or ionic interactions.

**[0044]** The polymer plugs of the invention is formed from an aqueous solution of one or more inverse thermosensitive polymers. These polymer solutions are liquids below body temperature and gel at about body temperature. The polymer solution is prepared external of the body, i.e., at a temperature below body temperature. The polymer solution may be further chilled to prolong the time the gel stays in the liquid form upon introduction into the body. A preferred temperature

is about 10 °C below the gelation temperature of the polymer solution.

**[0045]** In general, the inverse thermosensitive polymers used in the methods of the invention, which become a gel at or about body temperature, can be injected into a patient's body in a liquid form. The injected material upon reaching body temperature undergoes a transition from a liquid to a gel. The inverse thermosensitive polymers used in connection with the methods of the invention may comprise a block copolymer with inverse thermal gelation properties. The block copolymer can further comprise a polyoxyethylene-polyoxypropylene block copolymer, such as a biodegradable, biocompatible copolymer of polyethylene oxide and polypropylene oxide. Also, the inverse thermosensitive polymer can include a therapeutic agent.

**[0046]** The molecular weight of the inverse thermosensitive polymer is preferably between 1,000 and 50,000, more preferably between 5,000 and 35,000. Preferably the polymer is in an aqueous solution. For example, typical aqueous solutions contain about 5% to about 30% polymer, preferably about 10% to about 25%. The molecular weight of a suitable inverse thermosensitive polymer (such as a poloxamer or poloxamine) may be, for example, between 5,000 and 25,000, and more particularly between 7,000 and 20,000.

**[0047]** The pH of the inverse thermosensitive polymer formulation administered to the mammal is, generally, about 6.0 to about 7.8, which are suitable pH levels for injection into the mammalian body. The pH level may be adjusted by any suitable acid or base, such as hydrochloric acid or sodium hydroxide.

**[0048]** Suitable inverse thermosensitive polymers include polyoxyethylene-polyoxypropylene (PEO-PPO) block copolymers. Two examples are Pluronic® F127 and F108, which are PEO-PPO block copolymers with molecular weights of 12,600 and 14,600, respectively. Each of these compounds is available from BASF of Mount Olive, N.J. Pluronic® F108 at 12-25% concentration in phosphate buffered saline (PBS) is an example of a suitable inverse thermosensitive polymeric material. Pluronic® acid F127 at 12-25% concentration in PBS is another example of a suitable material. Low concentrations of dye (such as crystal violet), hormones, therapeutic agents, fillers, and antibiotics can be added to the inverse thermosensitive polymer. In general, other biocompatible, biodegradable PEO-PPO block copolymers that exist as a gel at body temperature and a liquid at below body temperature may also be used according to the present invention.

**[0049]** Notably, Pluronic® polymers have unique surfactant abilities and extremely low toxicity and immunogenic responses. These products have low acute oral and dermal toxicity and low potential for causing irritation or sensitization, and their general chronic and sub-chronic toxicity is low. In fact, Pluronic® polymers are among a small number of surfactants that have been approved by the FDA for direct use in medical applications and as food additives (BASF (1990) Pluronic® & Tetronic® Surfactants, BASF Co., Mount Olive, N.J.). Recently, several Pluronic® polymers have been found to enhance the therapeutic effect of drugs, and the gene transfer efficiency mediated by adenovirus (March K L, Madison J E, Trapnell B C. "Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implication for cardiovascular gene therapy" Hum. Gene Therapy 1995, 6, 41-53).

**[0050]** The average molecular weights of the poloxamers range from about 1,000 to greater than 16,000 daltons. Because the poloxamers are products of a sequential series of reactions, the molecular weights of the individual poloxamer molecules form a statistical distribution about the average molecular weight. In addition, commercially available poloxamers contain substantial amounts of poly(oxyethylene) homopolymer and poly(oxyethylene)/poly(oxypropylene) diblock polymers. The relative amounts of these byproducts increase as the molecular weights of the component blocks of the poloxamer increase. Depending upon the manufacturer, these byproducts may constitute from about 15 to about 50% of the total mass of the polymer.

**[0051]** The inverse thermosensitive polymers may be purified using a process for the fractionation of water-soluble polymers, comprising the steps of dissolving a known amount of the polymer in water, adding a soluble extraction salt to the polymer solution, maintaining the solution at a constant optimal temperature for a period of time adequate for two distinct phases to appear, and separating physically the phases. Additionally, the phase containing the polymer fraction of the preferred molecular weight may be diluted to the original volume with water, extraction salt may be added to achieve the original concentration, and the separation process repeated as needed until a polymer having a narrower molecular weight distribution than the starting material and optimal physical characteristics can be recovered.

**[0052]** In certain embodiments, a purified poloxamer or poloxamine has a polydispersity index from about 1.5 to about 1.0. In certain embodiments, a purified poloxamer or poloxamine has a polydispersity index from about 1.2 to about 1.0.

**[0053]** The aforementioned process consists of forming an aqueous two-phase system composed of the polymer and an appropriate salt in water. In such a system, a soluble salt can be added to a single phase polymer-water system to induce phase separation to yield a high salt, low polymer bottom phase, and a low salt, high polymer upper phase. Lower molecular weight polymers partition preferentially into the high salt, low polymer phase. Polymers that can be fractionated using this process include polyethers, glycols such as poly(ethylene glycol) and poly(ethylene oxide)s, polyoxyalkylene block copolymers such as poloxamers, poloxamines, and polyoxypropylene/ polyoxybutylene copolymers, and other polyols, such as polyvinyl alcohol. The average molecular weight of these polymers may range from about 800 to greater than 100,000 daltons. See U.S. Patent 6,761,824. The aforementioned purification process inherently exploits the dif-

ferences in size and polarity, and therefore solubility, among the poloxamer molecules, the poly(oxyethylene) homopolymer and the poly(oxyethylene)/poly(oxypropylene) diblock byproducts. The polar fraction of the poloxamer, which generally includes the lower molecular weight fraction and the byproducts, is removed allowing the higher molecular weight fraction of poloxamer to be recovered. The larger molecular weight poloxamer recovered by this method has physical characteristics substantially different from the starting material or commercially available poloxamer including a higher average molecular weight, lower polydispersity and a higher viscosity in aqueous solution.

**[0054]** Other purification methods may be used to achieve the desired outcome. For example, WO 92/16484 discloses the use of gel permeation chromatography to isolate a fraction of poloxamer 188 that exhibits beneficial biological effects, without causing potentially deleterious side effects. The copolymer thus obtained had a polydispersity index of 1.07 or less, and was substantially saturated. The potentially harmful side effects were shown to be associated with the low molecular weight, unsaturated portion of the polymer, while the medically beneficial effects resided in the uniform higher molecular weight material. Other similarly improved copolymers were obtained by purifying either the polyoxypropylene center block during synthesis of the copolymer, or the copolymer product itself (e.g., U.S. Pat. No. 5,523,492 and U.S. Pat. No. 5,696,298).

**[0055]** Further, a supercritical fluid extraction technique has been used to fractionate a polyoxyalkylene block copolymer as disclosed in U.S. Pat. No. 5,567,859. A purified fraction was obtained, which was composed of a fairly uniform polyoxyalkylene block copolymer having a polydispersity of less than 1.17. According to this method, the lower molecular weight fraction was removed in a stream of carbon dioxide maintained at a pressure of 2200 pounds per square inch (psi) and a temperature of 40 °C.

**[0056]** Additionally, U.S. Pat. No. 5,800,711 discloses a process for the fractionation of polyoxyalkylene block copolymers by the batchwise removal of low molecular weight species using a salt extraction and liquid phase separation technique. Poloxamer 407 and poloxamer 188 were fractionated by this method. In each case, a copolymer fraction was obtained which had a higher average molecular weight and a lower polydispersity index as compared to the starting material. However, the changes in polydispersity index were modest and analysis by gel permeation chromatography indicated that some low-molecular-weight material remained. The viscosity of aqueous solutions of the fractionated polymers was significantly greater than the viscosity of the commercially available polymers at temperatures between 10 °C and 37 °C, an important property for some medical and drug delivery applications. Nevertheless, some of the low molecular weight contaminants of these polymers are thought to cause deleterious side effects when used inside the body, making it especially important that they be removed in the fractionation process. As a consequence, polyoxyalkylene block copolymers fractionated by this process are not appropriate for all medical uses.

**[0057]** In a preferred embodiment, the polymers used are block polymers such as polyoxyethylene-polyoxypropylene (PEO-PPO) block polymers of the general structure A-B, (A-B)<sub>n</sub>, A-B-A (e.g., Pluronic®), or (A-B-A)<sub>n</sub> with A being the PEO part and B being the PPO part and n being greater than 1. In another preferred embodiment, the polymers used are branched polymers of polyoxyethylene-polyoxypropylene (PEO-PPO) like tetra-functional poloxamines (e.g., Tetronic®).

#### Methods of the Invention

**[0058]** The present invention provides an approach to the treatment of lithiasis. In one embodiment a polymer is injected between the inlet of a lumen and a calculi in said lumen to form a polymer plug which occludes the lumen; the subsequent action of peristalsis causes the polymer plug to traverse the lumen, forcing the calculi out of the lumen.

**[0059]** The present invention relates to a method of treating lithiasis, comprising the steps of:

45 injecting into a lumen of a mammal at a first distance upstream from a calculi a first composition comprising an inverse thermosensitive polymer, wherein said first composition does not contact said calculi; thereby forming a polymer plug;  
optionally injecting into said lumen at a second distance upstream from said calculi a second composition, wherein said second composition does not contact said calculi; and  
allowing peristalsis to cause said polymer plug to traverse said lumen, thereby forcing said calculi from said lumen.

**[0060]** The present invention relates to the aforementioned method, wherein said second composition is injected into said lumen.

**[0061]** The present invention relates to the aforementioned method, wherein said first position is between about 1 cm and about 5 cm upstream of said calculi.

**[0062]** The present invention relates to the aforementioned method, wherein said first position is between about 2 cm and about 4 cm upstream of said calculi.

**[0063]** The present invention relates to the aforementioned method, wherein said first position is about 3 cm upstream of said calculi.

[0064] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 3mm.

[0065] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 1mm.

5 [0066] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 0.5mm.

[0067] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 0.1mm.

10 [0068] The present invention relates to the aforementioned method, wherein said first composition is injected into said lumen through a percutaneous access device.

[0069] The present invention relates to the aforementioned method, wherein said first composition is injected into said lumen through a catheter or a syringe.

[0070] The present invention relates to the aforementioned method, wherein the catheter is a dual lumen catheter or a triple lumen catheter.

15 [0071] The present invention relates to the aforementioned method, wherein said lumen is or is a portion of a kidney, gall bladder, ureter, urinary bladder, pancreas, salivary gland, small intestine or large intestine.

[0072] The present invention relates to the aforementioned method, wherein said lumen is or is a portion of a ureter or kidney.

20 [0073] The present invention relates to the aforementioned method, wherein said calculi is a kidney stone, pancreatic stone, salivary stone, or biliary stone.

[0074] The present invention relates to the aforementioned method, wherein said calculi is a kidney stone.

[0075] The present invention relates to the aforementioned method, wherein said mammal is a human.

[0076] The present invention relates to the aforementioned method, wherein said second composition comprises a contrast-enhancing agent.

25 [0077] The present invention relates to the aforementioned method, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.

[0078] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is a block copolymer, random copolymer, graft polymer, or branched copolymer.

30 [0079] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is a block polymer or a branched copolymer.

[0080] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is an optionally purified poloxamer or poloxamine.

35 [0081] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is optionally purified and selected from the group consisting of poloxamine 1107, poloxamine 1307, poloxamer 338 and poloxamer 407.

[0082] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is an optionally purified poloxamer 407.

40 [0083] The present invention relates to the aforementioned method, wherein said first composition has a transition temperature of between about 10 °C and 40 °C.

[0084] The present invention relates to the aforementioned method, wherein said first composition has a transition temperature of between about 15 °C and 30 °C.

[0085] The present invention relates to the aforementioned method, wherein said first composition has a transition temperature of about 25 °C.

45 [0086] The present invention relates to the aforementioned method, wherein said first composition comprises about 5 % to about 30 % of said inverse thermosensitive polymer.

[0087] The present invention relates to the aforementioned method, wherein said first composition comprises about 10 % to about 25 % said inverse thermosensitive polymer.

50 [0088] The present invention relates to the aforementioned method, wherein the inverse thermosensitive polymer has a polydispersity index from about 1.5 to 1.0.

[0089] The present invention relates to the aforementioned method, wherein the inverse thermosensitive polymer has a polydispersity index from about 1.2 to 1.0.

[0090] The present invention relates to the aforementioned method, wherein the inverse thermosensitive polymer has a polydispersity index from about 1.1 to 1.0.

55 [0091] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is an optionally purified poloxamer or poloxamine; and said first composition has a transition temperature of between about 10 °C and 40 °C.

[0092] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is

an optionally purified poloxamer or poloxamine; and said first composition has a transition temperature of between about 15 °C and 30 °C.

[0093] The present invention relates to the aforementioned method, wherein said inverse thermosensitive polymer is an optionally purified poloxamer or poloxamine; and said first composition has a transition temperature of about 25 °C.

5 [0094] Another aspect of the present invention relates to a method of treating lithiasis, comprising the steps of:

injecting into a lumen of a mammal at a first distance upstream from a calculi a first composition, wherein said first composition does not contact said calculi;

10 injecting into said lumen at a second distance upstream from said calculi a second composition, wherein said second composition does not contact said calculi; wherein said first composition and said second composition admix, thereby forming a polymer plug;

allowing peristalsis to cause said polymer plug to traverse said lumen, thereby forcing said calculi from said lumen.

15 [0095] The present invention relates to the aforementioned method, wherein said second composition is injected into said lumen.

[0096] The present invention relates to the aforementioned method, wherein said first position is between about 1 cm and about 5 cm upstream of said calculi.

[0097] The present invention relates to the aforementioned method, wherein said first position is between about 2 cm and about 4 cm upstream of said calculi.

20 [0098] The present invention relates to the aforementioned method, wherein said first position is about 3 cm upstream of said calculi.

[0099] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 3mm.

25 [0100] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 1mm.

[0101] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 0.5mm.

[0102] The present invention relates to the aforementioned method, wherein the distance between said first position and said second position is less than about 0.1mm.

30 [0103] The present invention relates to the aforementioned method, wherein said first and second compositions are injected into said lumen through a percutaneous access device.

[0104] The present invention relates to the aforementioned method, wherein said first and second compositions are injected into said lumen through a catheter or a syringe.

35 [0105] The present invention relates to the aforementioned method, wherein the catheter is a dual lumen catheter or a triple lumen catheter.

[0106] The present invention relates to the aforementioned method, wherein said lumen is or is a portion of a kidney, gall bladder, ureter, urinary bladder, pancreas, salivary gland, small intestine or large intestine.

[0107] The present invention relates to the aforementioned method, wherein said lumen is or is a portion of a ureter or kidney.

40 [0108] The present invention relates to the aforementioned method, wherein said calculi is a kidney stone, pancreatic stone, salivary stone, or biliary stone.

[0109] The present invention relates to the aforementioned method, wherein said calculi is a kidney stone.

[0110] The present invention relates to the aforementioned method, wherein said mammal is a human.

45 [0111] The present invention relates to the aforementioned method, wherein said second composition comprises a contrast-enhancing agent.

[0112] The present invention relates to the aforementioned method, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.

50 **Exemplification**

[0113] The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

Example 1*Gelation Temperature of Selected Pluronic® and Tetronic® Polymer Solutions*

5 [0114] The polymer was weighed into a plastic tube. To achieve the required concentration the weight was multiplied by 4, for 25 weight percent (w%), and by 5, for 20 weight percent (w%), and the required final weight was achieved by adding saline. The solutions were placed in the fridge at 4 °C and usually were ready within 24 hours. Gelation points were measured in a Brookfield viscometer and the point at which viscosity exceeded the range of the plate/cone (greater than about 102,000 cP) was called the gelation temperature.

10

**Table 1**

Gelation Temperature of Selected Inverse Thermosensitive Polymer Solutions in Saline.		
<i>polymer</i>	<i>concentration</i>	<i>temperature</i>
Tetronic 1107	25 w%	27 °C
Tetronic 1107	20 w%	34 °C
Purified Tetronic 1107	25 w%	22 °C
Purified Tetronic 1107	20 w%	32.5 °C
Tetronic 1307	25 w%	24.5 °C
Tetronic 1307	20 w%	31 °C
Purified Tetronic 1307	25 w%	20 °C
Purified Tetronic 1307	20 w%	26 °C
Pluronic F108	25 w%	26 °C
Pluronic F108	20 w%	60 °C
Purified Pluronic F108	25 w%	19 °C
Purified Pluronic F108	20 w%	26 °C

Example 2*Gelation Temperature of Selected Pluronic® and Tetronic® Polymer Solutions with Iodinated Contrast Agent*

35 [0115] Purified polymers were weighed into 50 mL centrifuge tubes and a 1:1 mixture of saline and 100% Omnipaque 300 were added until a specific weight percentage was reached. Gelatin points were measured in a Brookfield viscometer and the point at which the viscosity exceeded the range of the plate/cone greater than about 102 Pa.s (about 102,000 cP) was called the gelation point. All solutions were further heated to 37 °C to ascertain that the material still exceeded the viscosity range and remained a gel. All gels passed.

40

**Table 2**

Gelation Temperature of Purified Inverse Thermosensitive Polymer Solutions containing 50 w% Omnipaque 300		
<i>polymer</i>	<i>concentration</i>	<i>temperature</i>
Purified Tetronic 1107	20 w%	24 °C
Purified Tetronic 1307	21 w%	26.5 °C
Purified Pluronic F108	18 w%	21.5 °C
Purified Pluronic F127	18 w%	18 °C

50

Example 3*Dissolution Time Under Static Conditions in Saline*

5 [0116] The dissolution of the purified poloxamer 407 gel was tested by injecting 0.5 milliliter of the gel into a petri dish covered in saline at 37 °C. The gel was visualized by small addition of methylene blue and the dissolution of the gel was followed visually. Two different shapes of the gels were used for the dissolution tests: a sphere which has the least amount of surface area; and a string, which has the highest surface area, in which a 20 gauge syringe was used to extrude the string of polymer onto the bottom of the Petri dish.

10 [0117] The petri dish was not disturbed and every minute, the petri dish was observed visually and complete dissolution was confirmed by swirling the petri dish.

[0118] The dissolution was dependent on the concentration of the polymer. The lower the polymer concentration, the faster the gel dissolved as depicted in the Figure 5. Further, the dissolution was dependent on the surface area in direct contact with the surrounding liquid, the sphere-shaped gel taking longer to dissolve than the string.

15 [0119] These in-vitro experiments probably still overestimate the real dissolution times as there was no pulsatile force on the gel, which would probably speed up the dissolution.

Example 4*Dissolution Time Under Static Conditions in Urine*

20 [0120] The dissolution of the 22.5% purified poloxamer 407 gel was tested by injecting 2.5 milliliter of the gel into a petri dish covered in about 100 mL urine at 37 °C. A syringe without a needle was used to extrude a string of polymer onto the bottom of the Petri dish. The gel was visualized by small addition of methylene blue and the dissolution of the gel was followed visually. Upon extrusion the string broke in two. The petri dish was not disturbed and every minute, the petri dish was observed visually and complete dissolution was confirmed by swirling the petri dish. The complete dissolution time (about 26 minutes) was identical for the two strings.

Example 5*Pig Ureter In-Vivo Experiments*

30 [0121] A 22.5 w% solution of purified Poloxamer PF127, colored with methylene blue, in a Medallion 5 ml syringe was used. In each of the three pigs, an artificial stone, made of plaster of Paris, was surgically implanted in the right ureter a few centimeters above the site of the incision. The solution was then injected behind the stone through the same incision site, using a 3F catheter [Embocath HIC 100 from BioSphere Medical, lot# 03W-6930]. Immediately prior to the injection the catheter was flushed with 10 cc of cold saline to keep it cool during the injection and avoid hardening of the polymer within the catheter. Each procedure was monitored with a camera inserted in the ureter between the stone and the incision site.

35 [0122] *Pig #1* -- 3 ml of solution were injected behind the stone that occluded ca. 1/4 to 1/3 of the cross-section of the ureter, and created a well visible blue polymer plug that completely occluded the ureter behind the stone. After a little over 1 minute, the polymer plug or some urine accumulating behind it created contraction waves of the ureteral walls (peristalsis) which forced the plug to slide forward towards the camera and out of the ureter, carrying with it the entire stone, without any need for lithotripsy.

40 [0123] *Pig #2* -- Same as the 1<sup>st</sup> pig but the stone was slightly larger, and immediately after the injection of the polymer lithotripsy (EHL) was used to break the stone into small fragments. Within one minute of the completion of lithotripsy peristalsis started and the stone debris were pushed by the sliding plug out of the ureter.

45 [0124] *Pig #3* -- Same as the 2<sup>nd</sup> pig but the stone was even larger. Within one minute of the completion of lithotripsy peristalsis started and the stone debris were pushed by the sliding plug out of the ureter.

50

**Claims**

55 1. A medicament comprising a first composition and optionally a second composition, for use in treating lithiasis in a lumen of a mammal, comprising the steps of:  
 injecting into a lumen of a mammal at a first position upstream from a calculi a first composition, wherein said first composition does not contact said calculi and wherein said first composition comprises an inverse thermo-

5 sensitive polymer;  
 optionally injecting into said lumen at a second position upstream from said calculi a second composition, wherein said second composition does not contact said calculi;  
 wherein (i) said first composition and said second composition admix to form the polymer plug; or (ii) said first composition alone forms a polymer plug; and  
 allowing peristalsis to cause said polymer plug to traverse said lumen, thereby forcing said calculi from said lumen.

10 2. The medicament for use according to claim 1, wherein said second composition is injected into said lumen.

15 3. The medicament for use according to claim 1 or claim 2, wherein said lumen is or is a portion of a kidney, gall bladder, ureter, urinary bladder, pancreas, salivary gland, small intestine or large intestine, preferably said lumen is or is a portion of a ureter or kidney.

20 4. The medicament for use according to any preceding claim, wherein said calculi is a kidney stone, pancreatic stone, salivary stone, or biliary stone, preferably a kidney stone.

25 5. The medicament for use according to any preceding claim, wherein said mammal is a human.

6. The medicament for use according to any preceding claim, wherein said second composition comprises a contrast-enhancing agent.

7. The medicament for use according to claim 6, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.

30 8. The medicament for use according to any preceding claim, wherein said first composition alone forms a polymer plug and wherein said inverse thermosensitive polymer is a block copolymer, random copolymer, graft polymer, or branched copolymer.

9. The medicament for use according to claim 8, wherein said inverse thermosensitive polymer is a block copolymer or a branched copolymer.

35 10. The medicament for use according to any of claims 1 to 7, wherein said first composition alone forms a polymer plug and wherein said inverse thermosensitive polymer is an optionally purified poloxamer or poloxamine.

11. The medicament for use according to claim 10, wherein said inverse thermosensitive polymer is optionally purified and selected from the group consisting of poloxamine 1107, poloxamine 1307, poloxamer 338, and poloxamer 407.

40 12. The medicament for use according to claim 11, wherein said inverse thermosensitive polymer is an optionally purified poloxamer 407.

13. The medicament for use according to any preceding claim, wherein said first composition alone forms a polymer plug and wherein said first composition has a transition temperature of between 10°C and 40°C.

45 14. The medicament for use according to any preceding claim, wherein said first composition alone forms a polymer plug and wherein said first composition comprises 5% to 30% of said inverse thermosensitive polymer.

15. The medicament for use according to any preceding claim, wherein said first composition alone forms a polymer plug and wherein the inverse thermosensitive polymer has a polydispersity index from 1.5 to 1.0.

#### Patentansprüche

55 1. Ein Arzneimittel, umfassend eine erste Zusammensetzung und gegebenenfalls eine zweite Zusammensetzung zur Verwendung bei der Behandlung von Lithiasis in einem Lumen eines Säugers, umfassend folgende Schritte:

Injizieren einer ersten Zusammensetzung in ein Lumen eines Säugers an einer ersten Position stromaufwärts

von Steinen, wobei die erste Zusammensetzung die Steine nicht berührt und wobei die erste Zusammensetzung ein inverses wärmeempfindliches Polymer umfasst;

gegebenenfalls Injizieren einer zweiten Zusammensetzung in das Lumen an einer zweiten Position stromaufwärts von den Steinen, wobei die zweite Zusammensetzung die Steine nicht berührt;

5 wobei (i) die erste Zusammensetzung und die zweite Zusammensetzung zur Bildung des Polymerstopfens vermengt werden, oder (ii) die erste Zusammensetzung allein einen Polymerstopfen bildet, und die Peristaltik veranlassen kann, dass der Polymerstopfen das Lumen durchquert, wodurch die Steine aus dem Lumen gezwungen werden.

10 2. Arzneimittel zur Verwendung nach Anspruch 1, wobei die zweite Zusammensetzung in das Lumen injiziert wird.

3. Arzneimittel zur Verwendung nach Anspruch 1 oder 2, wobei das Lumen ein(e) Niere, Gallenblase, Harnleiter, Harnblase, Bauchspeicheldrüse, Speicheldrüse, Dünndarm oder Dickdarm oder ein Teil davon ist; vorzugsweise ist das Lumen ein Harnleiter oder eine Niere oder ein Teil davon.

15 4. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei es sich bei den Steinen um einen Nierenstein, Pankreasstein, Speichelstein oder Gallenstein, vorzugsweise um einen Nierenstein handelt.

5. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei das Säugetier ein Mensch ist.

20 6. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die zweite Zusammensetzung ein kontrastverstärkendes Mittel umfasst.

7. Arzneimittel zur Verwendung nach Anspruch 6, wobei das kontrastverstärkende Mittel ausgewählt ist aus der Gruppe bestehend aus strahlungsundurchlässigen Materialien, paramagnetischen Materialien, Schweratomen, Übergangsmetallen, Lanthaniden, Actiniden, Farbstoffen und radionuklidhaltigen Materialien.

25 8. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die erste Zusammensetzung allein einen Polymerstopfen bildet und wobei das inverse wärmeempfindliche Polymer ein Blockcopolymer, ein Random-Copolymer, ein Ppropfpolymer oder ein verzweigtes Copolymer ist.

9. Arzneimittel zur Verwendung nach Anspruch 8, wobei das inverse wärmeempfindliche Polymer ein Blockcopolymer oder ein verzweigtes Copolymer ist.

30 10. Arzneimittel zur Verwendung nach einem der Ansprüche 1 bis 7, wobei die erste Zusammensetzung allein einen Polymerstopfen bildet und wobei das inverse wärmeempfindliche Polymer ein gegebenenfalls gereinigtes Poloxamer oder Poloxamin ist.

11. Arzneimittel zur Verwendung nach Anspruch 10, wobei das inverse wärmeempfindliche Polymer wahlweise gereinigt und ausgewählt ist aus der Gruppe bestehend aus Poloxamin 1107, Poloxamin 1307, Poloxamer 338 und Poloxamer 407.

35 12. Arzneimittel zur Verwendung nach Anspruch 11, wobei das inverse wärmeempfindliche Polymer ein gegebenenfalls gereinigtes Poloxamer 407 ist.

13. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die erste Zusammensetzung allein einen Polymerstopfen bildet und wobei die erste Zusammensetzung eine Übergangstemperatur zwischen 10 °C und 40 °C aufweist.

40 14. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die erste Zusammensetzung allein einen Polymerstopfen bildet und wobei die erste Zusammensetzung 5 % bis 30 % des inversen wärmeempfindlichen Polymers umfasst.

15. Arzneimittel zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die erste Zusammensetzung allein einen Polymerstopfen bildet und wobei das inverse wärmeempfindliche Polymer einen Polydispersitätsindex von 1,5 bis 1,0 aufweist.

## Revendications

1. Médicament comprenant une première composition et une seconde composition, éventuellement, pour traiter la lithiase dans une lumière d'un mammifère, comprenant les étapes consistant à :
  - injecter dans une lumière d'un mammifère en une première position en amont de calculs une première composition, où ladite première composition ne vient pas au contact desdits calculs et où ladite première composition comprend un polymère thermosensible inverse ;
  - injecter éventuellement dans ladite lumière à une seconde position en amont desdits calculs une seconde composition, où ladite seconde composition ne vient pas au contact desdits calculs ;
    - où (i) ladite première composition et ladite seconde composition se mélangent pour former le bouchon de polymère ; ou bien (ii) ladite première composition forme seule un bouchon de polymère ; et
    - permettre au péristaltisme de faire traverser ladite lumière par ledit bouchon de polymère, provoquant ainsi l'expulsion desdits calculs à partir de ladite lumière.
2. Médicament pour utilisation selon la revendication 1, où ladite seconde composition est injectée dans ladite lumière.
3. Médicament pour utilisation selon la revendication 1 ou la revendication 2, où ladite lumière est un rein, la vésicule biliaire, l'urètre, la vessie, le pancréas, une glande salivaire, l'intestin grêle ou le gros intestin ou bien est une partie de ceux-ci, de préférence ladite lumière est un uretère ou un rein ou bien est une partie de ceux-ci.
4. Médicament pour utilisation selon une quelconque revendication précédente, où lesdits calculs sont des calculs rénaux, des calculs pancréatiques, des calculs salivaires ou des calculs biliaires, de préférence des calculs rénaux.
5. Médicament pour utilisation selon une quelconque revendication précédente, où ledit mammifère est un humain.
6. Médicament pour utilisation selon une quelconque revendication précédente, où ladite seconde composition comprend un agent améliorant le contraste.
7. Médicament pour utilisation selon la revendication 6, où ledit agent améliorant le contraste est choisi dans le groupe constitué par les matériaux radio-opaques, les matériaux paramagnétiques, les atomes lourds, les métaux de transition, les lanthanides, les actinides, les colorants et les matières contenant des radionucléides.
8. Médicament pour utilisation selon une quelconque revendication précédente, où ladite première composition forme seule un bouchon de polymère et où ledit polymère thermosensible inverse est un copolymère à blocs, un copolymère aléatoire, un polymère greffé ou un copolymère ramifié.
9. Médicament pour utilisation selon la revendication 8, où ledit polymère thermosensible inverse est un copolymère à blocs ou un copolymère ramifié.
10. Médicament pour utilisation selon l'une quelconque des revendications 1 à 7, où ladite première composition forme seule un bouchon de polymère et où ledit polymère thermosensible inverse est un poloxamère ou une poloxamine éventuellement purifiés.
11. Médicament pour utilisation selon la revendication 10, où ledit polymère thermosensible inverse est éventuellement purifié et choisi dans le groupe constitué par la poloxamine 1107, la poloxamine 1307, le poloxamère 338 et le poloxamère 407.
12. Médicament pour utilisation selon la revendication 11, où ledit polymère thermosensible inverse est un poloxamère éventuellement purifié 407.
13. Médicament pour utilisation selon une quelconque revendication précédente, où ladite première composition forme seule un bouchon de polymère et où ladite première composition a une température de transition comprise entre 10°C et 40°C.
14. Médicament pour utilisation selon une quelconque revendication précédente, où ladite première composition forme seule un bouchon de polymère et où ladite première composition comprend 5 % à 30 % dudit polymère thermo-

sensible inverse.

**15.** Médicament pour utilisation selon une quelconque revendication précédente, où ladite première composition forme seule un bouchon de polymère et où le polymère thermosensible inverse a un indice de polydispersité de 1,5 à 1,0.

5

10

15

20

25

30

35


40

45

50

55

**Figure 1**



**Figure 2**




Figure 3






Figure 4



**Figure 5**



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 2005037062 A [0007]
- US 6761824 B [0053]
- WO 9216484 A [0054]
- US 5523492 A [0054]
- US 5696298 A [0054]
- US 5567859 A [0055]
- US 5800711 A [0056]

## Non-patent literature cited in the description

- *Bull. Korean Chem. Soc.*, 2002, vol. 23, 549-554 [0023]
- **MARCH K L ; MADISON J E ; TRAPNELL B C.** Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implication for cardiovascular gene therapy. *Hum. Gene Therapy*, 1995, vol. 6, 41-53 [0049]